Smith & Nephew Share Discussion Threads

[roguetraderuk] 22/4/2022 15:30

jnj reported strong growth in elective surgery hence the strength in the shares here. but looks like 200dma firmly rejected. what has been encouraging is that there has been no lower low than the feb low. maybe not a big deal elsewhere but for this name which has serially underperformed its a big deal. i have a half position just a few percent below current so not in a hurry to sell it but while capped by 200dma then some weakness likely. relative to index however its probably going to do a bit better.

[jonojubb] 22/4/2022 15:21

I sold up at 13.12 as it's frustrating to continue to hold while it swings from 12 to 13. Will buy again once it drops back down to 12, which I'm confident it will.

[chrisdgb] 21/4/2022 09:52

Would be nice to keep the positive traction going...

[kev0856153] 19/4/2022 15:40

Now up 3.3% for a 6% swing on the day

[kev0856153] 19/4/2022 12:27

Down 2.7% at one point this morning now at midday it's back to flat for the day. Strange behaviour for such a large cap

[marcela9] 14/4/2022 14:27

Agreed - with more people able to move around more freely, amd with surgeons now able to perform without distractions, backlogs for hip/knee replacements should slowly be reduced

[justiceforthemany] 09/4/2022 15:03

Surprised this is not moving higher. Other healthcare and pharma stocks up 20% in the last month or so. As summer approaches one would think elective backlog will be cleared and >half revenues are from USA.

[roguetraderuk] 23/2/2022 08:06

nice write up in the IC, worth a look. valuation is below its long term average (which it should be given the issues) but that leaves upside for improvement as performance improves. 19 times 22 and 17 times 23.

[justiceforthemany] 22/2/2022 14:52

Debt to equity <1
Equity ratio >2
Demand will soar as Covid hits the backburner.

[roguetraderuk] 22/2/2022 10:28

now reaching business equilibrium so should market perform. any more covid will set them back clearly but the business is back online. they are still not executing as they should optimally but no longer a leaking ship. if market declines further these can now be added to 1000-1150. fwd pe of 18 for 22 well below stryker at 25 but stryker executing perfectly. that is the level to aim for. if management doesnt do it, i expect jnj spin off will in a couple of year.

[csalvage] 22/2/2022 10:18

The results look good, maybe some momentum going forward.

[its the oxman] 15/2/2022 10:02

You would think so. Mkt not very forward looking for SN but very happy to price in returning demand for airlines and the like. Not sure what we are missing here.

[gclark] 08/2/2022 19:24

"NHS waiting list backlog will take years to clear"

Surely that means there will be higher than normal demand for several years? Isn't that a good thing?

[lonrho] 08/2/2022 15:58

FT has the consensus earnings from the 12 analysts covering the stock at 92 cents for 2022. That equals a p/e of just under 18 for this year.

[essentialinvestor] 08/2/2022 14:26

The high multiple is coming home to bute imv, a point I've made over the last 6 months.


23 x FY 2022 current consensus and risks on that arguably to the downside.

On current FY '23 the multiple still looks over 20 x.

[keyno] 08/2/2022 14:23

That's always the administrators' hope with these long waiting lists, PUG!

Others will be taking their place though.

[pugugly] 08/2/2022 14:18

More bad news likely to impact S&N - This time from UK.
NHS waiting list backlog will take years to clear


Remember in a way some of the S&N potential customers may well have passed over as a result of the waiting list delays.

[pugugly] 08/2/2022 12:23

Possible further falls once US opens on depending If fall of Zimmer Biomet Holdings continues from yesterday.

[gclark] 08/2/2022 08:05

I don't agree with the general business comments above, but I do see the supply issues and cancelled elective surgeries as the major stumbling blocks, but these should be transient.
I invest in stocks for the future prospects, and am probably a bit overweight here, but I see that enormous investment will go into clearing the backlog of surgeries that SN products are used in, and I believe they will get their market share of those surgeries so will hold.
You always wonder what the reasons are behind large share sales, and maybe there is a particular reason we don't know.
AIMHO

[trekker60] 07/2/2022 15:51

"Such a frustrating share"
Ain't it just! Bought in here a year before Covid appeared and am still sitting on a loss. But after such a long wait, I'm reluctant to sell out now so am reconciled to this 'investment' being dead money for a while yet until, hopefully, the company's fortubes benefit more significantly from global healthcare trends. Or there's a bid approach - but that has periodically been rumpoured for years and nothing has materalised so not holding my breath on that one. Yep, 'frustrating' is the word!

[laptop15] 07/2/2022 15:44

Why the drop here guys??

[roguetraderuk] 07/2/2022 15:37

underweight here. execution isnt there and india news yet to be put into mix. due to update 22nd feb. im interested in adding at 10ish and 7ish if seen. i expect the jnj arm once spun off will be in for these in a couple of years. stryker in the states has executed far better could be interested but there could be comp issues. medtronic will also report on 22nd feb, also having its own execution issues and on similar 22 pe of about 18. stryker, the better business is on 25 times. this year (22) should be better (less covid) and 23 far better (even less covid?) but its all about how they execute individually. back to sn. im underweight until they can turn the corner or price drops lower enough but a bidder to surface. we arent there yet on either front.

[kev0856153] 07/2/2022 15:29

It's at pandemic lows so I'm in.

[suetballs] 07/2/2022 14:14

Like the backlog of cases the rise in the share price is delayed!!!
Such a frustrating share.
Suet

[luzley] 25/1/2022 12:54

C/o Adastra LSE
ASC's are the real key for S&N to outperform25 Jan 2022 12:18
The light at the end of the Covid19 tunnel is now clearly visible and the engagement of Spire by the govt to assist the NHS in attacking the elective surgery backlog is heartening in the UK. I have my sights firmly set on the progress being made across the pond in the ASC (ambulatory surgical centres). The company is firing on all cylinders to capture market share here as a prime mover. The last acquisition and RNS on Jan 19th was music to my ears as is today's very useful director appointment. S&N are focussing on ASC's as they are lucrative, high-margin avenues in which S&N has firmly embedded itself. If you look at the range of indicators here it is exceptional - sports injury, repair and cemented/cementless knee replacement with SOTA robotics, the company is bang on the money. Add in the huge Malaysian facility due to open this year to service the far East and the recently announced Baltic region hub and you start to see the bigger picture.